FDA Intensifies Crackdown on GLP-1 Compounding
Summary
Agency proposal would exclude semaglutide, tirzepatide, and liraglutide from 503B bulks list
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.